Tegafur-uracil-induced rapid development of advanced hepatic fibrosis

Table 1 Laboratory data on admission

WBC	5750/μL	ALP	670 mg/dL	Type 4 collagen 7S	16 ng/mL
RBC	2.99 × 106/μL	LDH	386 mg/dL	Hyaluronic acid	653.4 ng/mL
Hb	11.7 g/dL	γGTP	97 U/L
PLT	5.3 × 106/μL	ChE	68 U/L	ANA	× 1280
		T. Cho	120 g/dL	(anti-centromere type)
PT%	40%	BUN	18.6 mg/dL	AMA	(-)
PT-INR	1.63	Cre	0.65 mg/dL	ASMA	(-)
		Na	140 mEq/L
T.P.	6.1 g/dL	K	3.9 mEq/L	HBs Ag	(-)
Alb	2.9 g/dL	Cl	105 mEq/L	HBc Ab	9.36 S/CO
T. Bil	1.7 mg/dL	NH3	44 µg/dL	HBV DNA	(-)
D. Bil	0.8 mg/dL	IgG	1591.2 mg/dL	HCV Ab	(-)
AST	130 U/L	IgA	636.4 mg/dL
ALT	80 U/L	IgM	107.4 mg/dL

WBC: White blood cell count; RBC: Red blood cell count; Hb: Hemoglobin; PLT: Platelet count; PT%: Prothrombin time; PT-INR: Prothrombin time-international normalized ratio; T.P.: Total protein; Alb: Albumin; T.Bil: Total bilirubin; D.Bil: Direct bilirubin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; LDH: Lactate dehydrogenase; γGTP: Gamma-glutamyl transferase; ChE: Cholinesterase; T.Cho: Total cholesterol; BUN: Blood urea nitrogen; Cre: Creatinine; NH3: Ammonia; IgG: Immunoglobulin G; IgA: Immunoglobulin A; IgM: Immunoglobulin M; ANA: Anti-nuclear antibody; AMA: Anti-mitochondrial antibody; ASMA: Anti-smooth muscle antibody; HBsAg; Hepatitis B surface antigen; HBcAb: Hepatitis B core antibody; HBV: Hepatitis B virus; HCV Ab: Hepatitis C virus antibody.

Table 2 Tegafur-uracil-induced hepatic fibrosis

Cases	Age (yr)	Sex	Daily dose (mg)	Duration (mo)	Type 4 collagen 7S (ng/mL)	Hepatic fibrosis	Portal hypertension
1[1]	81	M	400	48	12	Bridging fibrosis	Esophageal varices
							Ascites
2[3]	76	F	NA	24	NA	Bridging fibrosis	Ascites
3[4]	82	M	300	48	12	Bridging fibrosis	NA
4[4]	73	M	300	23	11	Bridging fibrosis	NA
5[4]	68	F	400	55	12	Bridging fibrosis	NA
Our case	74	F	400	8	16	Bridging fibrosis	Esophageal varices
						With septation	Ascites
							Splenomegaly

M: Male; F: Female; NA: Not available.